| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
314,885 |
257,581 |
$22.94M |
| J9271 |
Injection, pembrolizumab, 1 mg |
2,404 |
1,876 |
$18.02M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
161,589 |
144,904 |
$7.81M |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
102,428 |
31,482 |
$4.01M |
| J0897 |
Injection, denosumab, 1 mg |
2,830 |
2,669 |
$3.78M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
40,096 |
39,753 |
$3.72M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
1,348 |
984 |
$3.36M |
| 99223 |
Prolong inpt eval add15 m |
30,342 |
26,599 |
$3.09M |
| J9299 |
Injection, nivolumab, 1 mg |
487 |
346 |
$2.85M |
| 99233 |
Prolong inpt eval add15 m |
28,622 |
12,525 |
$1.69M |
| 99215 |
Prolong outpt/office vis |
17,849 |
16,706 |
$1.53M |
| J9022 |
Injection, atezolizumab, 10 mg |
201 |
151 |
$1.40M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
22,300 |
22,146 |
$1.38M |
| 99205 |
Prolong outpt/office vis |
11,992 |
11,828 |
$1.38M |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
14,370 |
14,088 |
$1.34M |
| 17110 |
|
23,932 |
21,004 |
$1.23M |
| 99222 |
Initial hospital care, per day, moderate complexity |
16,677 |
15,180 |
$1.18M |
| J9173 |
Injection, durvalumab, 10 mg |
190 |
138 |
$1.16M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
20,539 |
11,700 |
$958K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
10,257 |
10,100 |
$863K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
306 |
174 |
$859K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
2,998 |
2,124 |
$754K |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
978 |
294 |
$731K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
575 |
436 |
$636K |
| 10040 |
|
10,030 |
9,106 |
$634K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
2,339 |
2,265 |
$628K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
888 |
631 |
$583K |
| 52000 |
|
5,391 |
5,337 |
$559K |
| 59426 |
|
450 |
447 |
$409K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
7,923 |
7,821 |
$406K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
656 |
529 |
$366K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
68,554 |
54,859 |
$360K |
| Q5116 |
Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg |
313 |
227 |
$360K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
5,660 |
4,951 |
$359K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12,138 |
11,070 |
$356K |
| 52356 |
|
1,556 |
1,496 |
$349K |
| 59409 |
Vaginal delivery only (with or without episiotomy and/or forceps) |
447 |
441 |
$332K |
| 99385 |
|
3,223 |
3,198 |
$314K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
2,975 |
2,944 |
$299K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
10,019 |
6,751 |
$273K |
| J9306 |
Injection, pertuzumab, 1 mg |
67 |
51 |
$271K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
42,392 |
34,831 |
$268K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
4,486 |
4,287 |
$258K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
668 |
626 |
$256K |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
250 |
191 |
$254K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
8,743 |
5,136 |
$253K |
| 47562 |
|
683 |
675 |
$253K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
11,068 |
6,371 |
$250K |
| 99386 |
|
2,131 |
2,100 |
$240K |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
2,041 |
1,257 |
$231K |
| Q5122 |
Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg |
120 |
95 |
$230K |
| 93000 |
|
29,360 |
28,667 |
$222K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
1,863 |
637 |
$218K |
| 59025 |
Fetal non-stress test |
7,342 |
2,566 |
$203K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
5,068 |
4,880 |
$201K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
2,543 |
2,509 |
$200K |
| 96367 |
|
11,298 |
6,342 |
$190K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
1,762 |
1,757 |
$183K |
| 96417 |
|
6,435 |
4,095 |
$180K |
| 80047 |
|
21,170 |
16,445 |
$170K |
| 99220 |
|
1,827 |
1,769 |
$169K |
| 10060 |
|
2,412 |
2,248 |
$168K |
| 52310 |
|
1,197 |
1,186 |
$168K |
| 52332 |
|
2,087 |
1,984 |
$151K |
| Q5117 |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
58 |
39 |
$148K |
| 36415 |
Collection of venous blood by venipuncture |
55,059 |
49,277 |
$147K |
| 52352 |
|
1,161 |
1,086 |
$140K |
| 71046 |
Radiologic examination, chest; 2 views |
8,753 |
8,461 |
$136K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
14,064 |
7,689 |
$133K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
28,371 |
24,320 |
$130K |
| J9035 |
Injection, bevacizumab, 10 mg |
82 |
26 |
$130K |
| J1453 |
Injection, fosaprepitant, 1 mg |
3,113 |
2,051 |
$126K |
| J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units |
644 |
421 |
$121K |
| 93458 |
|
973 |
942 |
$118K |
| 43235 |
|
2,134 |
2,071 |
$116K |
| 96416 |
|
1,696 |
1,001 |
$115K |
| 59430 |
|
489 |
474 |
$112K |
| 76872 |
|
1,520 |
1,497 |
$111K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
810 |
802 |
$111K |
| 51728 |
|
802 |
800 |
$110K |
| 51798 |
|
18,457 |
17,830 |
$108K |
| J1756 |
Injection, iron sucrose, 1 mg |
2,831 |
1,548 |
$105K |
| 99442 |
|
2,540 |
2,472 |
$101K |
| 76801 |
|
1,481 |
1,390 |
$99K |
| 81003 |
|
57,177 |
53,811 |
$93K |
| 76818 |
|
1,288 |
648 |
$90K |
| 90838 |
|
1,538 |
1,188 |
$89K |
| 50590 |
|
282 |
281 |
$88K |
| 99219 |
|
1,303 |
1,255 |
$88K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
1,631 |
1,608 |
$87K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
4,421 |
1,741 |
$86K |
| 80305 |
|
10,234 |
8,971 |
$85K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
9,046 |
8,766 |
$85K |
| 31575 |
|
1,276 |
1,260 |
$83K |
| 11901 |
|
3,473 |
2,953 |
$83K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,945 |
1,931 |
$82K |
| 96411 |
|
3,622 |
2,241 |
$81K |
| 99496 |
|
738 |
719 |
$80K |
| 94060 |
|
3,390 |
3,322 |
$79K |
| 99495 |
|
908 |
891 |
$76K |
| 76770 |
|
1,343 |
1,327 |
$76K |
| 99195 |
|
1,354 |
1,149 |
$75K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,220 |
1,149 |
$74K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
5,115 |
2,744 |
$73K |
| 90837 |
Psychotherapy, 53 minutes with patient |
975 |
709 |
$73K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
697 |
694 |
$73K |
| 99441 |
|
2,642 |
2,340 |
$71K |
| 11102 |
|
1,377 |
1,346 |
$68K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
5,044 |
3,984 |
$67K |
| 55700 |
|
637 |
628 |
$66K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
991 |
980 |
$66K |
| 88112 |
|
2,190 |
2,159 |
$61K |
| 76830 |
Ultrasound, transvaginal |
872 |
858 |
$61K |
| 17004 |
|
682 |
587 |
$58K |
| 90682 |
|
973 |
965 |
$58K |
| 96402 |
|
4,125 |
3,852 |
$57K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
905 |
897 |
$54K |
| 99443 |
|
1,011 |
974 |
$53K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
376 |
375 |
$53K |
| J0185 |
Injection, aprepitant, 1 mg |
252 |
166 |
$50K |
| 99221 |
|
1,001 |
970 |
$49K |
| 96415 |
|
4,125 |
2,708 |
$49K |
| 99254 |
|
544 |
517 |
$48K |
| 95115 |
|
9,326 |
3,467 |
$48K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
7,376 |
7,252 |
$45K |
| 20610 |
|
2,979 |
2,498 |
$44K |
| 90674 |
|
1,821 |
1,796 |
$44K |
| 17000 |
|
2,032 |
1,829 |
$44K |
| 51700 |
|
1,294 |
1,196 |
$43K |
| 92557 |
|
2,039 |
2,022 |
$42K |
| 90756 |
|
2,038 |
1,978 |
$42K |
| 76813 |
|
618 |
609 |
$42K |
| 76820 |
|
1,503 |
883 |
$39K |
| J9070 |
Cyclophosphamide, 100 mg |
336 |
151 |
$39K |
| 76825 |
|
258 |
246 |
$39K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
2,311 |
2,286 |
$38K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
359 |
351 |
$37K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
281 |
281 |
$37K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
157 |
149 |
$36K |
| J9190 |
Injection, fluorouracil, 500 mg |
4,608 |
1,871 |
$34K |
| 52005 |
|
772 |
750 |
$34K |
| 99490 |
Ccm add 20min |
2,598 |
2,581 |
$34K |
| 96401 |
|
1,137 |
519 |
$34K |
| 59514 |
|
40 |
40 |
$34K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
3,481 |
1,032 |
$33K |
| 94729 |
|
1,277 |
1,273 |
$33K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
181 |
68 |
$32K |
| 94726 |
|
1,257 |
1,254 |
$31K |
| 69210 |
|
1,415 |
1,349 |
$31K |
| J9045 |
Injection, carboplatin, 50 mg |
1,920 |
1,236 |
$30K |
| 93298 |
|
1,567 |
1,511 |
$30K |
| 99406 |
|
4,717 |
4,593 |
$29K |
| 99217 |
|
815 |
790 |
$28K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
790 |
724 |
$28K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
567 |
491 |
$28K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
579 |
523 |
$26K |
| 74420 |
|
1,986 |
1,853 |
$25K |
| J3489 |
Injection, zoledronic acid, 1 mg |
1,105 |
1,013 |
$24K |
| 99255 |
|
213 |
207 |
$24K |
| 17003 |
|
1,332 |
1,237 |
$23K |
| 92567 |
|
2,565 |
2,486 |
$22K |
| 81002 |
|
10,515 |
9,744 |
$21K |
| 99497 |
|
1,090 |
1,008 |
$20K |
| 88121 |
|
88 |
88 |
$20K |
| J9041 |
Injection, bortezomib, 0.1 mg |
463 |
78 |
$20K |
| 93356 |
|
1,956 |
1,947 |
$20K |
| 90688 |
|
1,177 |
1,158 |
$20K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,293 |
677 |
$19K |
| 94750 |
|
426 |
424 |
$19K |
| 81025 |
|
3,017 |
2,942 |
$19K |
| 96368 |
|
2,689 |
1,625 |
$19K |
| J9267 |
Injection, paclitaxel, 1 mg |
1,361 |
561 |
$19K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
241 |
225 |
$18K |
| 99000 |
|
3,502 |
2,826 |
$18K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
439 |
426 |
$17K |
| 93015 |
|
667 |
663 |
$17K |
| 76942 |
|
840 |
824 |
$17K |
| 72110 |
|
700 |
673 |
$16K |
| 96127 |
|
5,872 |
5,495 |
$16K |
| J9395 |
Injection, fulvestrant, 25 mg |
102 |
90 |
$15K |
| 30520 |
|
40 |
40 |
$15K |
| 90686 |
|
900 |
890 |
$15K |
| 54150 |
|
241 |
241 |
$14K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
454 |
284 |
$14K |
| 82962 |
|
6,411 |
5,526 |
$14K |
| 51705 |
|
324 |
297 |
$13K |
| 81000 |
|
5,217 |
4,880 |
$13K |
| 94010 |
|
816 |
782 |
$13K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
3,528 |
3,358 |
$13K |
| 92928 |
|
51 |
39 |
$13K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
13,024 |
11,617 |
$13K |
| 93299 |
|
237 |
228 |
$13K |
| 99152 |
|
1,884 |
1,758 |
$12K |
| 73030 |
|
870 |
801 |
$12K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
902 |
630 |
$12K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
13,569 |
7,630 |
$12K |
| 99407 |
|
895 |
860 |
$12K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
412 |
384 |
$12K |
| 64615 |
|
216 |
215 |
$12K |
| 51797 |
|
170 |
168 |
$12K |
| 76857 |
|
545 |
538 |
$11K |
| 0001A |
|
309 |
307 |
$11K |
| 0002A |
|
287 |
286 |
$11K |
| 90834 |
Psychotherapy, 45 minutes with patient |
247 |
200 |
$11K |
| 51702 |
|
372 |
348 |
$11K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
1,304 |
1,211 |
$10K |
| 73630 |
|
564 |
501 |
$10K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,581 |
952 |
$10K |
| J2785 |
Injection, regadenoson, 0.1 mg |
99 |
99 |
$10K |
| 93351 |
|
170 |
165 |
$10K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
111 |
111 |
$10K |
| 80053 |
Comprehensive metabolic panel |
1,315 |
1,097 |
$9K |
| 90715 |
|
298 |
293 |
$9K |
| 92552 |
|
533 |
511 |
$9K |
| 11900 |
|
274 |
270 |
$9K |
| 82247 |
|
4,027 |
3,085 |
$9K |
| 93308 |
|
513 |
481 |
$8K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
2,310 |
2,224 |
$8K |
| J3490 |
Unclassified drugs |
2,512 |
1,270 |
$8K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
113 |
110 |
$8K |
| 90836 |
|
179 |
152 |
$8K |
| G0498 |
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion |
316 |
190 |
$8K |
| 90670 |
|
54 |
54 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,467 |
5,951 |
$7K |
| 92555 |
|
543 |
517 |
$7K |
| J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
399 |
230 |
$7K |
| 14040 |
|
29 |
29 |
$7K |
| 99225 |
|
654 |
492 |
$7K |
| 11103 |
|
177 |
175 |
$7K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
6,602 |
5,882 |
$7K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
248 |
119 |
$7K |
| 54161 |
|
89 |
88 |
$7K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
74 |
70 |
$6K |
| 96377 |
|
936 |
706 |
$6K |
| G0008 |
Administration of influenza virus vaccine |
2,019 |
1,972 |
$6K |
| J9171 |
Injection, docetaxel, 1 mg |
126 |
97 |
$6K |
| 90732 |
|
89 |
88 |
$6K |
| 99235 |
|
65 |
64 |
$6K |
| 93325 |
|
858 |
831 |
$6K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
16 |
14 |
$6K |
| 92550 |
|
454 |
442 |
$5K |
| 90673 |
|
85 |
85 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
454 |
448 |
$5K |
| J1626 |
Injection, granisetron hydrochloride, 100 mcg |
2,199 |
986 |
$5K |
| 93018 |
|
694 |
680 |
$5K |
| 0012A |
|
133 |
132 |
$5K |
| 96160 |
|
1,958 |
1,936 |
$5K |
| 52351 |
|
33 |
29 |
$4K |
| 73560 |
|
288 |
277 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
355 |
250 |
$4K |
| 76000 |
|
827 |
782 |
$4K |
| 51741 |
|
929 |
912 |
$4K |
| 95806 |
|
95 |
95 |
$4K |
| 0011A |
|
123 |
122 |
$4K |
| 92540 |
|
68 |
68 |
$4K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
93 |
79 |
$4K |
| 58300 |
|
57 |
56 |
$4K |
| 99218 |
|
119 |
113 |
$4K |
| 92587 |
|
873 |
829 |
$4K |
| 0031A |
|
105 |
105 |
$4K |
| J9206 |
Injection, irinotecan, 20 mg |
398 |
154 |
$4K |
| 80061 |
Lipid panel |
502 |
475 |
$3K |
| 93295 |
|
171 |
171 |
$3K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
312 |
249 |
$3K |
| 51784 |
|
184 |
181 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
650 |
526 |
$3K |
| 99201 |
|
122 |
122 |
$3K |
| 95816 |
|
27 |
27 |
$3K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
5,906 |
3,237 |
$3K |
| 96523 |
|
209 |
198 |
$3K |
| 0004A |
|
86 |
86 |
$3K |
| 92941 |
|
12 |
12 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
523 |
494 |
$3K |
| 90662 |
|
455 |
413 |
$3K |
| 93296 |
|
257 |
257 |
$3K |
| 49650 |
|
14 |
13 |
$3K |
| 84153 |
|
156 |
149 |
$3K |
| 85651 |
|
1,429 |
1,391 |
$3K |
| 73562 |
|
139 |
119 |
$3K |
| 93297 |
|
69 |
69 |
$2K |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
923 |
875 |
$2K |
| 90677 |
|
13 |
13 |
$2K |
| J2010 |
Injection, lincomycin hcl, up to 300 mg |
315 |
289 |
$2K |
| 76775 |
|
81 |
77 |
$2K |
| 99234 |
|
30 |
25 |
$2K |
| 90661 |
|
73 |
72 |
$2K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
41 |
41 |
$2K |
| 73130 |
|
151 |
110 |
$2K |
| 93312 |
|
38 |
38 |
$2K |
| 11308 |
|
29 |
24 |
$2K |
| 55250 |
|
12 |
12 |
$2K |
| 99306 |
Prolong nursin fac eval 15m |
22 |
21 |
$2K |
| 11402 |
|
27 |
25 |
$2K |
| 85060 |
|
176 |
172 |
$2K |
| 90658 |
|
177 |
160 |
$2K |
| 51720 |
|
114 |
53 |
$2K |
| 93248 |
|
141 |
141 |
$2K |
| 95811 |
|
14 |
14 |
$2K |
| 95251 |
|
112 |
111 |
$2K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
25 |
25 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
27 |
27 |
$2K |
| G0180 |
Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
180 |
180 |
$2K |
| 99051 |
|
446 |
426 |
$2K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
121 |
62 |
$2K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
177 |
173 |
$2K |
| 73502 |
|
97 |
94 |
$2K |
| 82947 |
|
622 |
572 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
379 |
354 |
$2K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
809 |
452 |
$2K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
25 |
25 |
$2K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
52 |
25 |
$2K |
| 64450 |
|
141 |
138 |
$2K |
| 82570 |
|
514 |
507 |
$2K |
| 91320 |
|
30 |
30 |
$2K |
| 0134A |
|
52 |
52 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
807 |
434 |
$1K |
| 77080 |
|
130 |
124 |
$1K |
| 92015 |
Determination of refractive state |
130 |
130 |
$1K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
207 |
205 |
$1K |
| 82043 |
|
355 |
352 |
$1K |
| 93320 |
|
96 |
96 |
$1K |
| 90656 |
|
71 |
71 |
$1K |
| 96409 |
|
38 |
13 |
$1K |
| 93244 |
|
105 |
102 |
$1K |
| 51610 |
|
55 |
51 |
$1K |
| 99384 |
|
12 |
12 |
$1K |
| 95024 |
|
13 |
13 |
$1K |
| 64566 |
|
27 |
13 |
$1K |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
225 |
196 |
$1K |
| 92537 |
|
54 |
54 |
$1K |
| 95117 |
|
151 |
73 |
$1K |
| 11303 |
|
15 |
13 |
$1K |
| 90694 |
|
214 |
211 |
$1K |
| 0013A |
|
30 |
30 |
$1K |
| Q2037 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) |
77 |
73 |
$1K |
| 85610 |
|
399 |
310 |
$1K |
| 52281 |
|
13 |
13 |
$1K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
56 |
56 |
$1K |
| 30901 |
|
12 |
12 |
$1K |
| 93290 |
|
47 |
39 |
$989.29 |
| 11104 |
|
14 |
14 |
$979.02 |
| 54056 |
|
12 |
12 |
$939.18 |
| 0124A |
|
38 |
37 |
$921.77 |
| 58301 |
|
15 |
15 |
$920.78 |
| 99224 |
|
186 |
165 |
$915.64 |
| 80076 |
|
272 |
216 |
$908.04 |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
52 |
47 |
$904.11 |
| 92551 |
|
128 |
125 |
$903.86 |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
51 |
26 |
$867.08 |
| 97750 |
|
204 |
188 |
$836.76 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
318 |
304 |
$831.91 |
| J1071 |
Injection, testosterone cypionate, 1 mg |
1,124 |
971 |
$794.35 |
| G9008 |
Coordinated care fee, physician coordinated care oversight services |
68 |
68 |
$754.87 |
| 99401 |
|
34 |
34 |
$731.50 |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
14 |
13 |
$730.50 |
| 92978 |
|
16 |
12 |
$725.46 |
| 99310 |
Prolong nursin fac eval 15m |
16 |
12 |
$712.96 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
2,686 |
2,582 |
$683.72 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
143 |
120 |
$660.91 |
| 93246 |
|
107 |
106 |
$659.34 |
| 90480 |
|
42 |
42 |
$634.52 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,310 |
742 |
$616.69 |
| 0003A |
|
16 |
16 |
$614.69 |
| 11721 |
|
28 |
28 |
$614.06 |
| 74018 |
|
37 |
37 |
$598.74 |
| 87077 |
|
106 |
99 |
$589.88 |
| 94664 |
|
151 |
144 |
$581.85 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
55 |
55 |
$575.00 |
| 92625 |
|
14 |
14 |
$566.08 |
| 87088 |
|
92 |
86 |
$565.19 |
| 83735 |
|
130 |
87 |
$556.98 |
| 93242 |
|
85 |
82 |
$548.61 |
| 99305 |
|
27 |
26 |
$526.98 |
| 83615 |
|
218 |
174 |
$516.49 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
113 |
104 |
$497.95 |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
316 |
168 |
$495.40 |
| 93350 |
|
13 |
13 |
$494.64 |
| 99153 |
Mod sedat endo service >5yrs |
380 |
342 |
$486.39 |
| 99451 |
|
26 |
26 |
$482.50 |
| 92553 |
|
25 |
25 |
$473.35 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
16 |
13 |
$453.36 |
| G2058 |
Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). |
23 |
21 |
$448.65 |
| 76870 |
|
13 |
12 |
$436.74 |
| 84100 |
|
239 |
183 |
$435.89 |
| 84550 |
|
228 |
172 |
$420.84 |
| 82044 |
|
133 |
130 |
$420.23 |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
354 |
310 |
$396.27 |
| 86580 |
|
90 |
86 |
$363.62 |
| 73110 |
|
19 |
13 |
$357.71 |
| 92250 |
|
17 |
17 |
$352.47 |
| 87186 |
|
47 |
43 |
$335.59 |
| 93922 |
|
13 |
13 |
$307.81 |
| 92547 |
|
69 |
68 |
$277.67 |
| 72100 |
|
15 |
15 |
$275.52 |
| 45330 |
|
12 |
12 |
$275.04 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
346 |
339 |
$252.60 |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
25 |
12 |
$232.55 |
| 76376 |
|
53 |
52 |
$232.15 |
| 97802 |
|
526 |
504 |
$210.00 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
66 |
62 |
$184.91 |
| J2060 |
Injection, lorazepam, 2 mg |
486 |
230 |
$182.78 |
| 51701 |
|
12 |
12 |
$173.81 |
| G0136 |
Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months |
38 |
38 |
$146.90 |
| G9007 |
Coordinated care fee, scheduled team conference |
12 |
12 |
$144.06 |
| 36591 |
|
63 |
48 |
$113.12 |
| G0403 |
Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report |
21 |
21 |
$109.68 |
| J3480 |
Injection, potassium chloride, per 2 meq |
103 |
64 |
$102.98 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
2,695 |
2,593 |
$96.52 |
| G0009 |
Administration of pneumococcal vaccine |
42 |
42 |
$89.18 |
| 90653 |
|
34 |
34 |
$83.49 |
| 3074F |
|
50,923 |
47,103 |
$81.23 |
| 0296T |
|
13 |
12 |
$73.82 |
| Q2039 |
Influenza virus vaccine, not otherwise specified |
15 |
15 |
$72.01 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
758 |
720 |
$66.67 |
| 3078F |
|
40,788 |
38,117 |
$65.60 |
| 86689 |
|
12 |
12 |
$64.12 |
| 81001 |
|
25 |
25 |
$55.25 |
| 3079F |
|
29,724 |
28,054 |
$54.00 |
| 93321 |
|
12 |
12 |
$41.60 |
| 82270 |
|
14 |
14 |
$29.32 |
| 3075F |
|
16,270 |
15,476 |
$28.87 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
15 |
13 |
$26.38 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
92 |
80 |
$25.31 |
| 94761 |
|
1,313 |
1,281 |
$25.00 |
| 1000F |
|
7,248 |
6,766 |
$23.39 |
| 0298T |
|
12 |
12 |
$21.51 |
| 3077F |
|
13,013 |
12,342 |
$16.00 |
| 99072 |
|
5,931 |
3,723 |
$15.25 |
| 3008F |
|
27,927 |
25,677 |
$12.42 |
| 4013F |
|
3,662 |
3,581 |
$11.24 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
7,607 |
7,058 |
$6.02 |
| G9275 |
Documentation that patient is a current non-tobacco user |
6,507 |
6,239 |
$6.01 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
1,824 |
1,729 |
$6.00 |
| 3080F |
|
10,010 |
9,495 |
$5.76 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
4,482 |
4,318 |
$5.01 |
| 0502F |
|
1,051 |
758 |
$1.38 |
| 4010F |
|
3,561 |
3,422 |
$0.98 |
| 1160F |
|
4,237 |
4,129 |
$0.32 |
| 2028F |
|
243 |
224 |
$0.18 |
| 1159F |
|
6,760 |
6,458 |
$0.16 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
4,231 |
3,997 |
$0.09 |
| 3051F |
|
659 |
652 |
$0.08 |
| 1033F |
|
1,302 |
1,176 |
$0.06 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
300 |
278 |
$0.06 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
7,080 |
6,241 |
$0.05 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
8,425 |
7,386 |
$0.05 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
5,819 |
4,949 |
$0.02 |
| 4000F |
|
419 |
366 |
$0.02 |
| 3052F |
|
117 |
115 |
$0.02 |
| G8482 |
Influenza immunization administered or previously received |
151 |
111 |
$0.01 |
| 3044F |
|
5,250 |
5,124 |
$0.01 |
| 3014F |
|
54 |
53 |
$0.01 |
| 1170F |
|
224 |
219 |
$0.01 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
13 |
13 |
$0.01 |
| 3046F |
|
495 |
478 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
704 |
673 |
$0.00 |
| 3725F |
|
672 |
661 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
389 |
359 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
3,639 |
3,279 |
$0.00 |
| 3288F |
|
58 |
57 |
$0.00 |
| 91300 |
|
181 |
162 |
$0.00 |
| 3045F |
|
361 |
346 |
$0.00 |
| 91313 |
|
46 |
46 |
$0.00 |
| G9276 |
Documentation that patient is a current tobacco user |
265 |
265 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
32 |
24 |
$0.00 |
| G8511 |
Screening for depression documented as positive, follow-up plan not documented, reason not given |
16 |
15 |
$0.00 |
| 99071 |
|
429 |
421 |
$0.00 |
| 90611 |
|
89 |
85 |
$0.00 |
| 3015F |
|
12 |
12 |
$0.00 |
| 4004F |
|
108 |
103 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
46 |
45 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
44 |
43 |
$0.00 |
| 3028F |
|
12 |
12 |
$0.00 |
| 99409 |
|
40 |
33 |
$0.00 |
| S9470 |
Nutritional counseling, dietitian visit |
40 |
39 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
17 |
17 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
13 |
13 |
$0.00 |
| 2022F |
|
12 |
12 |
$0.00 |
| 3050F |
|
12 |
12 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
1,748 |
1,684 |
$0.00 |
| 3017F |
|
320 |
307 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
2,141 |
1,958 |
$0.00 |
| G9664 |
Patients who are currently statin therapy users or received an order (prescription) for statin therapy |
170 |
149 |
$0.00 |
| G8432 |
Depression screening not documented, reason not given |
4,951 |
4,710 |
$0.00 |
| 1036F |
|
3,026 |
2,891 |
$0.00 |
| 0500F |
|
488 |
484 |
$0.00 |
| 1111F |
|
189 |
185 |
$0.00 |
| 4086F |
|
4,431 |
4,306 |
$0.00 |
| G9226 |
Foot examination performed (includes examination through visual inspection, sensory exam with 10-g monofilament plus testing any one of the following: vibration using 128-hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold, and pulse exam; report when all of the 3 components are completed) |
65 |
63 |
$0.00 |
| 4011F |
|
2,520 |
2,473 |
$0.00 |
| 3048F |
|
98 |
80 |
$0.00 |
| 1123F |
|
180 |
171 |
$0.00 |
| 4008F |
|
2,259 |
2,221 |
$0.00 |
| 3351F |
|
470 |
459 |
$0.00 |
| 3353F |
|
43 |
43 |
$0.00 |
| 99024 |
|
83 |
76 |
$0.00 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
299 |
279 |
$0.00 |
| 1034F |
|
259 |
241 |
$0.00 |
| G9189 |
Beta-blocker therapy prescribed or currently being taken |
57 |
53 |
$0.00 |
| 91301 |
|
119 |
119 |
$0.00 |
| 3011F |
|
162 |
133 |
$0.00 |
| 2010F |
|
141 |
130 |
$0.00 |
| 91303 |
|
40 |
40 |
$0.00 |
| G9281 |
Screening performed and documentation that vaccination not indicated/patient refusal |
57 |
57 |
$0.00 |
| Q3014 |
Telehealth originating site facility fee |
130 |
122 |
$0.00 |
| 1101F |
|
99 |
96 |
$0.00 |
| 1125F |
|
14 |
14 |
$0.00 |
| G8428 |
Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given |
58 |
56 |
$0.00 |
| 1006F |
|
13 |
13 |
$0.00 |
| 3061F |
|
12 |
12 |
$0.00 |
| 36416 |
|
13 |
13 |
$0.00 |
| 3352F |
|
16 |
16 |
$0.00 |
| H0038 |
Self-help/peer services, per 15 minutes |
15 |
12 |
$0.00 |